Actively Recruiting
Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis
Led by China-Japan Friendship Hospital · Updated on 2025-02-10
40
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. The comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. The safety and effectiveness will be compared to determine the relative merits of the two treatment methods.
CONDITIONS
Official Title
Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with subglottic stenosis through laryngoscopic examination or imaging studies such as CT.
- Experiencing symptoms related to subglottic stenosis, such as breathing difficulties, hoarseness, etc.
You will not qualify if you...
- Severe cardiopulmonary dysfunction, patients extremely debilitated and unable to tolerate the procedure.
- Patients allergic to lidocaine, midazolam, triamcinolone, or any of their components.
- Pregnant or lactating women.
- Unstable angina, congestive heart failure, severe bronchial asthma.
- Severe hypertension and arrhythmias, hemodynamically unstable, and severe respiratory failure (PaO2 <60mmHg after oxygen therapy or mechanical ventilation).
- Known coagulation dysfunction, inability to stop anticoagulants, antiplatelet agents, aspirin, or nonsteroidal anti-inflammatory drugs before treatment.
- Patients do not agree to participate in this study.
- Participation in other studies within the last three months and not withdrawn or concluded, or having received triamcinolone treatment less than 1 month ago.
- Researchers believe there are any circumstances making the patient unsuitable for inclusion.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
G
Gang Hou, PI
CONTACT
M
Mingming Deng, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here